Compare Biogen Inc (BIIB) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Clear Secure Inc — how do they compare? Biogen Inc trades at $209.2 (market cap $30.13B), while Clear Secure Inc trades at $46.44 (market cap $4.98B). The key difference: Biogen Inc is far larger — about 6.1× Clear Secure Inc's market cap, and Clear Secure Inc pays a 1.19% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | YOU | |
|---|---|---|
Market Cap | $30.13B | $4.98B |
Sector | Health | Technology |
52-Week High | $216.63 | $62.36 |
52-Week Low | $128.93 | $29.61 |
Enterprise Value | $37.20B | $4.13B |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
CLEAR Secure (YOU) trades at $46.98, down 8.26% in 24 hours, reflecting recent bearish pressure but holding above key support at $45. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $0.49 per share, revenue growth to $1.0 billion in 2026, and robust profitability margins. Technical indicators are mixed, with moving averages bearish but oscillators like RSI suggesting potential oversold conditions. Recent news highlights expansion in identity verification services and corporate memberships.
Outlook is cautiously optimistic due to earnings beats and growth initiatives, but risks include high valuation multiples and market volatility. Analysts are divided with a near-even buy/hold split, indicating balanced sentiment. Investors should weigh strong operational cash flow against competitive pressures in the identity security sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
